Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

MARKSANS PHARMA LTD. - 524404 - Compliance Certificate As Per Regulation 7(3) For FY Ended 31St March, 2023.

 As per the requirement of Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that all the activities in relation to share transfer facility of Marksans Pharma Limited during the period from 1st April, 2022 to 31st March, 2023 (both days inclusive) are maintained by M/s. Bigshare Services Pvt. Ltd., Category I Registrar and Share Transfer Agent registered with SEBI vide Registration No. INR000001385.
11-04-2023
Bigul

MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window

 In terms of the Company''s code of conduct to regulate, monitor and report trading by designated persons framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window for dealing in the shares of Marksans Pharma Limited ('the Company') for the designated persons of the Company will remain closed from Saturday, 1st April, 2023 till 48 hours after the declaration of audited financial results for the quarter and financial year ended 31st March, 2023. The date of declaration of audited financial results will be intimated separately in due course of time. Designated Persons of the Company and/or their immediate relatives shall not trade in the shares of the Company during the aforesaid period of closure of trading window.
31-03-2023
Bigul

Broker's Call: Marksans Pharma (Buy)

 HDFC Securities
16-03-2023
Bigul

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015

 Form C Disclosure under Insider Trading Regulations
16-03-2023
Bigul

MARKSANS PHARMA LTD. - 524404 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sandra Saldanha & PACs
16-03-2023

Marksans Pharma climbs 2% after USFDA approval for Famotidine tablets

 Famotidine tablets are bioequivalent to the reference listed drug Pepcid AC tablets, a registered trademark of Johnson Johnson Consumer Inc, which has sales of over $200 million in the US market.
10-03-2023
Bigul

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Marksans Pharma Limited announces US FDA approval for Famotidine Tablets USP, 10 mg and 20 mg.
10-03-2023
Bigul

MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
09-03-2023
Bigul

MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
03-03-2023
Bigul

MARKSANS PHARMA LTD. - 524404 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sandra Saldanha & PACs
01-03-2023
Next Page
Close

Let's Open Free Demat Account